Chronic Heart FailureNCT06683001
National Heart Failure Registry
An observational study of Chronic Heart Failure, run by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation at 1 site in Russia.
Trial summary
A prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the Russian Federation. The study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Heart Failure
- How many people
- 20,000 participants
- Where
- 1 siteRussia
- Study dates
- 1 Oct 2024to 31 Dec 2027
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: At least 3% of CHF subjects in the target regions of Russia will be included in that trial by performing thier medical records analysis
Who may be able to join
- Any stage and/or any class of CHF
Who cannot join
- Subjects whose source records cant be obtained for the analysis
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Organization
Moscow
Olga N Svirida, MD, PhD, ONSvirida@Cardio.ru
About this study
Official title: CHaracterization Of the STate of the System of Care for Patients With Chronic Heart Failure in the Regions of the Russian Federation: Identification, Diagnostics, Treatment, Observation
A prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the Russian Federation.
The study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the method of surgical intervention) and examination.
A control observation group is not intended.
Read the detailed description
The study will include retrospective and prospective data of patients with an outpatient or inpatient diagnosis of CHF.
The duration of the observation period of an individual patient with CHF is limited by the study period, or the patient's death, and includes the studied retrospective and dynamic prospective parameters. Prospective data of CHF (any stage and FC) subjects are planned to be included sequentially as they appear in inpatient CHF centers and outpatient CHF offices until 12/31/2027 inclusive and further upon extension of the study.
Retrospective data will be provided by chief freelance cardiologists of 33 constituent entities of the Russian Federation (Central Federal District, Ural Federal District, Siberian Federal District, Far Eastern Federal District) (individually, according to agreement)
- Conditions
- Chronic Heart Failure
What is being measured
The primary outcome is the main question the study is designed to answer.
Age of subjects with different phenotypes and stages of CHF
Measured: Every 12 months, up to 3 years
Female to male sex ratio of subjects with different phenotypes and stages of CHF
Measured: Every 12 months, up to 3 years
Clinical status of subjects with different phenotypes and stages of CHF
Measured: Every 12 months, up to 3 years
Proportion of employable and working subjects with different phenotypes and stages of CHF
Measured: Every 12 months, up to 3 years
The proportion of subjects with different algorithms for diagnosing CHF and the proportion of subjects with a verified diagnosis of CHF (established according to the recommended algorithm for diagnosing CHF)
Measured: Every 12 months, up to 3 years
The proportion of subjects taking drugs of each class and all four classes of the recommended four-component therapy regimen (in the overall choice and in different phenotypes of CHF; working/non-working age; working/non-working)
Measured: Every 12 months, up to 3 years
Number and proportion of subjects with wearable devices when using an online tool for identifying subjects with CHF with indications for high-tech medical care
Measured: Every 12 months, up to 3 years
Number and proportion of subjects when using an online tool for identifying subjects with CHF with indications for high-tech medical care
Measured: Every 12 months, up to 3 years
Secondary outcomes (14)
Proportions of subjects with an increase in EF ≥10% and a decrease in the functional class of CHF by 1 point
Measured: Every 12 months, up to 3 years
The proportion of subjects hospitalized for decompensated CHF in the departments of therapeutic and cardiology profiles *
Measured: Every 12 months, up to 3 years
Proportion of subjects with newly diagnosed type 2 diabetes*
Measured: Every 12 months
Proportion of subjects with deterioration of renal function*
Measured: Every 12 months, up to 3 years
Proportion of subjects with newly diagnosed malignant neoplasm*
Measured: Every 12 months, up to 3 years
Proportion of subjects who died from CV causes*
Measured: Every 12 months, up to 3 years
Proportion of subjects with different causes of death*
Measured: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for hospitalizations due to HF*
Measured: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for death from CV causes*
Measured: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for death from any cause*
Measured: Every 12 months, up to 3 years
The proportion of subjects with preferential drug provision for cardiovascular disease, diabetes mellitus*
Measured: Every 12 months, up to 3 years
Average frequency of outpatient visits of subjects with CHF to medical institutions*
Measured: Every 12 months, up to 3 years
The proportion of subjects registered with a cardiologist or therapist with different phenotypes and stages of CHF*
Measured: Every 12 months, up to 3 years
Average frequency of telephone patronage *
*- in the overall sample and in groups of subjects with HFrEF, HFmrEF, HFpEF and in different age categories (18-49 years; 50-64 years; 65-74 years; 75-85 years;\>85 years); of working/non-working age; employed/non-employed
Measured: Every 12 months, up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2024
- Study start1 Oct 2024
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 20,000 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Sergey A Boytsov, Prof., Study chair, E.I.Chazov Cardiology CenterZoya N Blankova, MD, PhD, Study director, E.I.Chazov Cardiology CenterFail' T Ageev, Prof., Principal investigator, E.I.Chazov Cardiology Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06683001
- Sponsor's protocol ID
- HOSTa CHF
- Other IDs
- ХОСТА ХСН
- Status last verified
- Apr 2026
- First submitted
- 7 Nov 2024
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CHaracterization Of the STate of the System of Care for Patients With Chronic Heart Failure in the Regions of the Russian Federation: Identification, Diagnostics, Treatment, Observation
- ClinicalTrials.gov ID
- NCT06683001
- Acronym / sponsor ID
- HOSTa CHF
- Conditions
- Chronic Heart Failure
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian FederationOther government
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 12 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the Russian Federation.
The study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the method of surgical intervention) and examination.
A control observation group is not intended.
Detailed description
The study will include retrospective and prospective data of patients with an outpatient or inpatient diagnosis of CHF.
The duration of the observation period of an individual patient with CHF is limited by the study period, or the patient's death, and includes the studied retrospective and dynamic prospective parameters. Prospective data of CHF (any stage and FC) subjects are planned to be included sequentially as they appear in inpatient CHF centers and outpatient CHF offices until 12/31/2027 inclusive and further upon extension of the study.
Retrospective data will be provided by chief freelance cardiologists of 33 constituent entities of the Russian Federation (Central Federal District, Ural Federal District, Siberian Federal District, Far Eastern Federal District) (individually, according to agreement)
Study design
- Observational model
- Other
- Time perspective
- Other
- Target follow-up
- 3 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- At least 3% of CHF subjects in the target regions of Russia will be included in that trial by performing thier medical records analysis
Key inclusion criteria (1 listed)
- Any stage and/or any class of CHF
Key exclusion criteria (1 listed)
- Subjects whose source records cant be obtained for the analysis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Age of subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
Female to male sex ratio of subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
Clinical status of subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
Proportion of employable and working subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
The proportion of subjects with different algorithms for diagnosing CHF and the proportion of subjects with a verified diagnosis of CHF (established according to the recommended algorithm for diagnosing CHF)
Time frame: Every 12 months, up to 3 years
The proportion of subjects taking drugs of each class and all four classes of the recommended four-component therapy regimen (in the overall choice and in different phenotypes of CHF; working/non-working age; working/non-working)
Time frame: Every 12 months, up to 3 years
Number and proportion of subjects with wearable devices when using an online tool for identifying subjects with CHF with indications for high-tech medical care
Time frame: Every 12 months, up to 3 years
Number and proportion of subjects when using an online tool for identifying subjects with CHF with indications for high-tech medical care
Time frame: Every 12 months, up to 3 years
14 secondary outcomes
Proportions of subjects with an increase in EF ≥10% and a decrease in the functional class of CHF by 1 point
Time frame: Every 12 months, up to 3 years
The proportion of subjects hospitalized for decompensated CHF in the departments of therapeutic and cardiology profiles *
Time frame: Every 12 months, up to 3 years
Proportion of subjects with newly diagnosed type 2 diabetes*
Time frame: Every 12 months
Proportion of subjects with deterioration of renal function*
Time frame: Every 12 months, up to 3 years
Proportion of subjects with newly diagnosed malignant neoplasm*
Time frame: Every 12 months, up to 3 years
Proportion of subjects who died from CV causes*
Time frame: Every 12 months, up to 3 years
Proportion of subjects with different causes of death*
Time frame: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for hospitalizations due to HF*
Time frame: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for death from CV causes*
Time frame: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for death from any cause*
Time frame: Every 12 months, up to 3 years
The proportion of subjects with preferential drug provision for cardiovascular disease, diabetes mellitus*
Time frame: Every 12 months, up to 3 years
Average frequency of outpatient visits of subjects with CHF to medical institutions*
Time frame: Every 12 months, up to 3 years
The proportion of subjects registered with a cardiologist or therapist with different phenotypes and stages of CHF*
Time frame: Every 12 months, up to 3 years
Average frequency of telephone patronage *
Time frame: Every 12 months, up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Heart Failure
Active, not recruiting
Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data
Chronic Heart Failure, Heart Transplant Recipient
Recruiting
Vasopressor Agents in Pulmonary Hypertension Crisis
Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 4
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Not yet recruitingPhase 3
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
Heart Failure Due to Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sergey A Boytsov, Prof. study chair
E.I.Chazov Cardiology Center
Zoya N Blankova, MD, PhD study director
E.I.Chazov Cardiology Center
Fail' T Ageev, Prof. principal investigator
E.I.Chazov Cardiology Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Heart Failure, run by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Olga N Svirida, MD, PhD (+74954146552, ONSvirida@Cardio.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Age of subjects with different phenotypes and stages of CHF (time frame: Every 12 months, up to 3 years). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.